Answers are grounded in this paper and cite their sources.
As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects. (ClinicalTrials.gov number, NCT00073307 [ClinicalTrials.gov].).
No takes yet. Share an insight, caveat, or question.
Escudier et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: